Rapid, repeatable, and highly sensitive assessment of contrast vision
In the long history of measuring human sight, the tools have often been as burdensome as the conditions they sought to diagnose — until now. A Boston startup called PerZeption, working alongside global ophthalmology leader Alcon, has validated a cloud-based vision assessment platform capable of delivering clinically meaningful results in under three minutes, on a standard tablet, from nearly anywhere. Presented at ARVO 2026, the collaboration marks a moment when the weight of specialized equipment and lengthy chair time may finally begin to lift — and when the question of how well we see becomes easier, and more honestly, answered.
- Traditional vision testing has long demanded specialized rooms, bulky equipment, and trained technicians — a system that doesn't scale and leaves patients waiting.
- PerZeption's AIM+ platform disrupts this model by running adaptive psychophysical tests on standard tablets, adjusting difficulty in real time to pinpoint a patient's true visual threshold without wasted effort.
- Validation data shows that just six adaptive stimulus displays with two repeats can achieve 90 percent statistical power to detect a one JND shift in contrast sensitivity across roughly twenty subjects — the precision pharmaceutical trials demand.
- Alcon's partnership lends institutional credibility to what was once a startup's promise, signaling that major ophthalmology players see this not as novelty but as infrastructure.
- The platform's cloud-based, self-administered design opens the door to remote testing — a capability that has been nearly impossible in vision care until now, and one that could fundamentally reshape clinical and research workflows.
A Boston startup called PerZeption has partnered with Alcon, one of the world's largest ophthalmology firms, to validate a technology that measures contrast sensitivity — the ability to distinguish objects from their background — in under three minutes, with results that are repeatable and clinically meaningful.
The partnership grew from a shared frustration with how vision testing has traditionally worked: slow, equipment-heavy, and difficult to scale. PerZeption's answer is a cloud-based platform that runs on standard tablets and computers, using adaptive psychophysical testing — a method that adjusts the difficulty of visual tasks in real time based on patient responses, homing in on actual visual thresholds without wasting time on stimuli that are too easy or too hard.
The validation data, presented at the ARVO annual meeting on May 4, 2026, is striking in its precision. With just six adaptive stimulus displays and two repeats, researchers can test around twenty subjects and achieve 90 percent statistical power to detect a one JND — a just noticeable difference — in contrast sensitivity. The assessment showed no systematic bias and demonstrated stable repeatability, meeting the bar that pharmaceutical companies and clinical researchers require when evaluating whether a treatment actually works.
Because the platform is cloud-based and self-administered, it can operate in a clinic, a patient's home, or anywhere with a tablet and an internet connection. PerZeption's flagship system can test more than twenty different visual functions, including some for which no other device currently exists — making remote vision assessment a practical reality rather than an aspiration.
The ARVO presentation, paired with a live demonstration at booth 4027, represents the kind of inflection point that defines a technology's trajectory: a startup moves from proof-of-concept to validation by a recognized industry leader, and the broader research community gets to see it work. Whether pharmaceutical trials, clinics, and the wider vision care industry follow is the open question — but the data, and the partnership, suggest the momentum is real.
A Boston-based startup called PerZeption is bringing a new kind of speed to an old problem: measuring how well someone can see. The company has partnered with Alcon, one of the world's largest ophthalmology firms, to validate a technology that can assess contrast sensitivity—the ability to distinguish objects from their background—in less than three minutes, with results that are both repeatable and clinically meaningful.
The partnership emerged from a shared recognition that vision testing, as it has traditionally been practiced, is cumbersome. Patients sit in specialized rooms with bulky equipment designed to do one thing. The process takes time. It requires trained technicians. It doesn't scale easily. PerZeption's approach is different. The company has built a cloud-based platform that runs on standard tablets and computers, using what it calls adaptive psychophysical testing—a method that adjusts the difficulty of visual tasks in real time based on how a patient responds, zeroing in on their actual visual threshold rather than wasting time on stimuli they can easily see or cannot see at all.
The validation data, which PerZeption will present at the Association of Research in Vision and Ophthalmology annual meeting on May 4, 2026, shows something striking: with just six adaptive displays of visual stimuli and two repeats, researchers can test around twenty subjects and achieve 90 percent statistical power to detect a one JND—a just noticeable difference—in contrast sensitivity. That's the kind of sensitivity pharmaceutical companies and clinical researchers need when they're evaluating whether a new treatment or correction method actually works. The technology completed its assessment in under three minutes, showed no systematic bias, and demonstrated stable repeatability across tests.
Dr. Jan Skerswetat, speaking for PerZeption, emphasized the significance of working with Alcon. "The results indicate that our technology enables rapid, repeatable, and highly sensitive assessment of contrast vision," he said, noting that Dr. Derek Nankivil would present the findings. The collaboration signals that a major player in ophthalmology sees real value in this approach—not just as a curiosity, but as a tool that could reshape how vision is measured in both clinical settings and pharmaceutical trials.
The broader context matters here. Vision correction and treatment evaluation has historically relied on subjective measures—asking patients which lens is better—or on equipment that is expensive, immobile, and requires significant patient time. Remote testing has been nearly impossible. PerZeption's platform changes the equation. Because it's cloud-based and self-administered, it can run in a clinic, in a patient's home, or anywhere with a tablet and an internet connection. The company's flagship platform, called Angular Indication Measurement, can test more than twenty different visual functions, including some for which no other device currently exists.
At the ARVO meeting, PerZeption will not only present the validation data but also demonstrate the technology at booth 4027, where attendees can try it themselves. This is the kind of moment that matters in medical technology: when a startup moves from proof-of-concept to validation by a recognized leader, and when the broader research community gets a chance to see it work. The question now is whether this validation opens doors—whether pharmaceutical companies begin using it in trials, whether clinics start adopting it to reduce patient burden, whether the vision care industry begins to shift toward faster, more accessible testing. The data suggests it should.
Notable Quotes
The results indicate that our technology enables rapid, repeatable, and highly sensitive assessment of contrast vision.— Dr. Jan Skerswetat, PerZeption
The Hearth Conversation Another angle on the story
Why does it matter that this test takes three minutes instead of, say, twenty?
Because time is a real constraint in clinical practice. Every minute in the chair is a minute the patient isn't somewhere else, and it's a minute the clinic can't see another patient. But more importantly, shorter tests mean fewer dropouts, less fatigue, and more reliable results. A tired patient gives worse data.
The abstract mentions "clinically meaningful visual differences." What does that actually mean?
It means the test can detect changes that matter in real life—not just statistical noise. If a new lens or treatment improves your vision, this test will catch it. That's what pharmaceutical companies and researchers need to know: does this intervention actually work, or is any improvement just measurement error?
Why is Alcon's involvement significant?
Alcon is massive—they're not a startup betting on an unproven idea. Their involvement is a validation signal. It says a company with billions in revenue and decades of expertise looked at this technology and decided it was worth their time and resources to collaborate on it.
Can this technology work remotely?
Yes, that's one of its real advantages. It runs on a tablet with cloud-based software. A patient could theoretically take the test at home and send the results to their doctor. That opens up possibilities for monitoring, follow-up testing, and research that weren't feasible before.
What's the catch?
The real test is adoption. Technology is only useful if clinics and researchers actually use it. There's inertia in medicine—people trust what they know. PerZeption has to convince the field that this is better enough to change workflows.